Rheumatoid Arthritis
📧 Sign up to get email alerts when something new happens for Rheumatoid Arthritis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-08-21Clinical Trial Update: A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis [Phase 2]
Phase IIb study of ALX-0061 as monotherapy in rheumatoid arthritis completed; results posted in 2019.
-
FDA approval · 2019-08-16FDA Approved: RINVOQ — Original Application (AbbVie Inc.)
This FDA page documents the original FDA approval of Rinvoq (upadacitinib) from AbbVie under NDA211675, marking the first approval of this J…
-
CLINICAL_TRIALS trial_result · 2019-08-16Clinical Trial Update: Prospective Evaluation of the Radiographic Efficacy of Enbrel
Completed clinical trial investigating radiographic efficacy of Enbrel in rheumatoid arthritis and psoriatic arthritis; results posted in 20…
-
CLINICAL_TRIALS trial_result · 2019-08-14Clinical Trial Update: Atorvastatin vs Colchicine in Decrease of Troponin I of High Sensitivity in Patients With Rheumatoid Arthritis. [Phase 2]
Phase 2 trial comparing atorvastatin and colchicine for lowering high-sensitivity troponin I in patients with rheumatoid arthritis; study co…
-
CLINICAL_TRIALS trial_result · 2019-08-14Clinical Trial Update: Safety, Tolerability and Efficacy of MBS2320 in Patients With Rheumatoid Arthritis [Phase 2]
A Phase 2 clinical trial assessing safety, tolerability, and efficacy of MBS2320 in patients with rheumatoid arthritis has been completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-08-12Clinical Trial Update: A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT) [Phase 3]
A Phase 3 trial of ocrelizumab vs placebo in active rheumatoid arthritis patients non-responsive to anti-TNF-α therapy was terminated; resul…
-
CLINICAL_TRIALS trial_result · 2019-08-08Clinical Trial Update: Lipopolysaccharide (LPS) or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Challenge Study on Healthy Subjects [Phase 1]
A Phase 1 clinical trial assessing LPS or GM-CSF challenge in healthy subjects, with conditions including rheumatoid arthritis; completed wi…
-
FDA approval · 2019-08-07FDA Approved: CELECOXIB — Original Application (AiPing Pharmaceutical, Inc.)
The FDA approved AiPing Pharmaceutical, Inc.'s original ANDA for celecoxib, establishing a generic version of the COX-2 inhibitor. The appro…
-
FDA approval · 2019-07-25FDA Approved: XELJANZ — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA entry describing a supplemental application for XELJANZ (tofacitinib) submitted by Pfizer Laboratories Div Pfizer Inc.
-
FDA approval · 2019-07-25FDA Approved: CELECOXIB — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application for celecoxib from Apotex Corp., granting approval for a generic version of the product.
-
FDA approval · 2019-07-25FDA Approved: CELECOXIB — Supplemental Application (Aurobindo Pharma Limited)
FDA approves Aurobindo Pharma Limited's supplemental application for Celecoxib (generic Celecoxib), confirming the generic's approval. Celec…
-
FDA approval · 2019-07-25FDA Approved: XELJANZ XR — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for XELJANZ XR (tofacitinib extended-release), expanding its formulation under Pfizer's submission.
-
CLINICAL_TRIALS trial_result · 2019-07-24Clinical Trial Update: Study to Compare the Efficacy of Tocilizumab With or Without Glucocorticoid Discontinuation in Rheumatoid Arthritis Participants [Phase 4]
Phase 4 trial comparing tocilizumab with versus without glucocorticoid discontinuation in rheumatoid arthritis completed; results posted in …
-
FDA approval · 2019-07-23FDA Approved: RUXIENCE — Original Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved Ruxience (rituximab-pvvr) from Pfizer as a biosimilar to rituximab, under an original application; the approval covers multiple…
-
FDA approval · 2019-07-23FDA Approved: HADLIMA — Original Application (Organon LLC)
FDA approves Hadlima (adalimumab-bwwd) from Organon as a biosimilar to Humira under the original application BLA761059. It is indicated for …
-
FDA approval · 2019-07-22FDA Approved: IBUPROFEN — Supplemental Application (Amneal Pharmaceuticals of New York LLC)
FDA approved Amneal Pharmaceuticals of New York LLC's supplemental application for a generic ibuprofen product. The approval confirms the ge…
-
FDA approval · 2019-07-22FDA Approved: IBUPROFEN — Supplemental Application (Chartwell RX, LLC)
The FDA approved a supplemental application for ibuprofen from Chartwell RX, LLC under ANDA 202413, authorizing the specified changes to thi…
-
CLINICAL_TRIALS trial_result · 2019-07-22Clinical Trial Update: APRIL (AbatacePt in Rheumatoid Arthritis-ILD) [Phase 2]
Phase 2 clinical trial update for APRIL (AbatacePt in Rheumatoid Arthritis-ILD) evaluating abatacept in rheumatoid arthritis with interstiti…
-
FDA approval · 2019-07-22FDA Approved: IBUPROFEN — Supplemental Application (Amneal Pharmaceuticals of New York LLC)
FDA approved a supplemental application for ibuprofen by Amneal Pharmaceuticals of New York LLC.
-
CLINICAL_TRIALS trial_result · 2019-07-19Clinical Trial Update: An Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of ALX-0061 in Subjects With Rheumatoid Arthritis [Phase 2]
Open-label extension study in rheumatoid arthritis assessing long-term efficacy and safety of ALX-0061 (Phase 2).
-
CLINICAL_TRIALS trial_result · 2019-07-15Clinical Trial Update: Sidus Stem-Free Shoulder IDE Study [NA]
Clinical trial update for a Sidus Stem-Free Shoulder IDE study has completed with results posted in 2019.
-
EMA safety_alert · 2019-07-12PRAC recommends new measures to avoid dosing errors with methotrexate
The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) recommends new measures to prevent dosing errors with methotrexate, including e…
-
CLINICAL_TRIALS trial_result · 2019-07-05Clinical Trial Update: An Evaluation of the Optimal Dose of Tofacitinib Needed to Achieve Low Disease Activity (LDA) or Clinical Remission in Patients With Active Rheumatoid Arthritis (RA) as Measured From a Clinical and Structural Perspective [Phase 3]
A Phase 3 trial evaluating the optimal dose of tofacitinib to achieve low disease activity or clinical remission in active rheumatoid arthri…
-
CLINICAL_TRIALS research · 2019-07-05Clinical Trial Update: A Belgian Registry of HUMIRA® (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis ( ProAct )
A completed registry study evaluating HUMIRA (adalimumab) in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, with res…
-
CLINICAL_TRIALS trial_result · 2019-07-02Clinical Trial Update: Assessment of Clinical Effectiveness and Safety of Adalimumab and High Dose Methotrexate in Routine Clinical Practice
A completed clinical trial evaluating the effectiveness and safety of adalimumab with high-dose methotrexate in routine clinical practice fo…